U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07540286) titled 'An Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism' on April 13.
Brief Summary: XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism. Previous clinical studies have demonstrated the safety of subcutaneously administered XH-02 in several patients with hypoparathyroidism and have yielded clear efficacy results. This study aims to further validate the safety and efficacy of subcutaneously injected XH-02 in the treatment of hypoparathyroidism in a expanded cohort.
Study St...